Tether (USDT) Supply Hits New High Amid Heightened Market Activity

TheCryptoTimes2025-10-16 tarihinde yayınlandı2025-10-16 tarihinde güncellendi

The supply of Tether (USDT) stablecoin is growing, with it now sitting at 181 billion in circulation. The recent mintings added over 4.5 billion in USDT supply to meet rising demand from institutions and on-chain trading, showing that stablecoins remain a key part of crypto markets.

As per DeFiLlama data, USDT supply currently amounts to total $181.406 billion, suggesting the total supply as 181.4 billion as each token is backed by $1 in collateral. It dominates the stablecoin sector with nearly 60% shares, followed by Circle’s USDC with 24.6% and a supply of 75.7 billion tokens. 

Stablecoins Overview - Defilama
Source: DeFiLlama

Surge in stablecoin supply in 2025 

The stablecoin market has experienced a remarkable surge in supply throughout 2025. It was largely driven by growing institutional adoption, favorable regulatory developments, and increasing demand for stable digital assets. By mid-2025, the total stablecoin supply surpassed $300 billion and it is projected to increase to $ 400 billion by year-end at this pace of growth. 

This surge, highlighted by a record $15.6 trillion in transfer volumes during Q3 2025, underscores stablecoins’ role as a cornerstone of the digital economy, particularly in DeFi and cross-border payments. 

Ethereum’s dominance in hosting 69% of new issuances, coupled with centralized stablecoins like USDT and USDC accounting for 90% of the market, reflects the sector’s robust expansion, potentially catalyzing broader cryptocurrency market growth as adoption reaches a mainstream tipping point. 

Stablecoins are increasingly bridging traditional finance and decentralized networks. It also enables cross-border stablecoin transfers, reducing settlement times from days to hours and lowering fees from about 2% to 0.3%. By combining regulatory compliance with automated DeFi processes, it shows how stablecoins can be used beyond basic trading.

Also Read: Mastercard, Chainlink Use CCIP to Bring Payments Onchain


Mobile Only Image

İlgili Okumalar

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit28 dk önce

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit28 dk önce

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit28 dk önce

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit28 dk önce

İşlemler

Spot
活动图片